# **Membranoproliferative GN (MPGN)/C3GN**
## **Overview**
  * MPGN
    1. Is a descripter of a pattern of injury that can be associated with different disease states
    2. Implies that the pathogenic process has been occuring for some time and other patterns of injury may present as well (endocapillary proliferative, mesangioproliferative, and crescent GN)
    3. Historically had three classifications, but such nominclature/classification has fallen out of favor due to rise of immunflorscent staining increase in understanding of how the injury occurs
  * Cases of MPGN w/sole or dominant C3/C4 staining are classified as primary GN
  * C3 glomerulopathy is a rare entity that commenly presents in an MPGN pattern of injury and can be delinated in to two categories: C3 glmerulonephritis (C3GN) and Dense Deposition Disease (DDD)
    1. C3GN
        - Primarly found in adults
        - Older age associateed more w/Monocolonal gammopathy and has better out comes
        - Can be acquired or genetic
        - Commnonly induced by C3 nephritic factors
    2. DDD
        - Primarly children and adolescents of both genders
        - Typically very agressive disease with deterioration of renal function ending ESKD
    3. typically leads to ESKD
    4. Has high reoccurance in tranplant patients and is a cause of early graft failure
  * C4 glomerulopathy is more rare than C3, and has two catorgies similar to C3: C4GN and DDD
## **Pathophysiology**
  * MPGN
    1. Pathology:
        - Glomerular Capillary wall remodeling (double countr formation or "train track" appearance
        - Endocapillary proliferation/hypercellularity
        - Subendothelial deposits
        - Pathogenesis: Glomerular capillary injury from deposits mesangial or subendothelial found by EM
    3. Pathologic entities:
        - Immune Complex GN (ICGN)
            1. AB triggures reation of classic and lectin pathway (cancers, Infection, allergic auto-immune)
            2. Systemic Autoimmune disease
            3. Infection
            4. Fibrillary GN
        - Paraprotein-mediated GN
            1. PGNMID (proliferative glomerulonephritis w/monoconol immunoglobulin deposits
            2. Cryoglobulinemia 
        - Complement-mediated GN
            1. <ins>*Dysregulation of the Alternative pathway*</ins> (genetic or auto-antibioty or monocolonal)
            2. C3GN
            3. DDD
            4. Novel/Rare C4 glomerulopathy
        - Chronic TMA
            1. Membrane double contour, but no prliferation
            2. aHUS/HUS
            3. Drug associated
            4. APS (antiphospholipid syndrome)
  * C3
    1. <ins>*Dysregulation of the Alternative pathway*</ins> (genetic or auto-antibioty or monocolonal)
    2. C3 dominant/only staining of glomerular deposits
    3. Around 50% of cases have and MPGN pattern of injury
    4.  C3GN
        - mesangial or subendothelial deposts on EM
        - Mesangial Deposits: 99%
        - Capillary wall deposits: 97%
        - w/humps 49%
        - Post-infectious GN can mimic C3GN (hypocomplementemia and proteinuria tend to normalize and C4d staining is positive in post-infectious GN)
    5. DDD
        - Intramembrnous dense deposits: 100%
        - w/humps 25%
        - "saugage-like appearance" on EM due to dense depositio of the basement membrane
## **Clinical Presentation**
  * Hematuria
  * Worsening eGFR/rising serum Cr
  * Severe Proteinuria
  * C3GN: low serum C3 levels (50% of cases) and normal serum C4 levles
  * Chronic deterioration of renal function
  * HTN
## **Drugs and Disease Associated with MPGN/C3GN**
  * ICGN
    1. SLE
    2. RA
    3. Sjogren's
    4. Mixed connective tissues disease
    5. Drug induced
  * Infectous
    1. Bacterial: post strep
    2. Viral: HCV (including HCV -mixed cryogloblinemia), HBV
    3. Paracytic: Malaria, schistosomiosis, mycoplasma, leighmaniasis, filariasis, histoplasmosis
  * Fibrillary GN
    1. Polyconol subendotheial deposits 
## **Treatment**
### MPGN on Biopsy
```mermaid
---
config:
  theme: redux
---
flowchart TD
    A(["MGPN Pattern on Bx"]) --> n1["Positive IgG
    pos/neg C3"] & n2["Complement Dominate Pattern"] & n3["Negative IgG
    Negative C3"]
    n1 --> n4(["IgG/C3 mediated"])
    n2 --> n6(["Complement mediated"])
    n3 --> n7["**Evaluate for the following**
    • Antiphospholipid syndrome
    • HUS/TMA
    • Sickle Cell
    • Polycythemia
    • Other"]
    n6 --> n8["Rule Out Infectious causes"]
    n4 --> n9["**Evaluate for the follow**
    • Monocolonal Gammopathy
    • Infection
    • Idopathic"]
    n9 --> n10["• SPEP
• UPEP
• Free light chains
• Heme/onc consult for Bonemarow Bx
• Age appropriate Cancer screenging"] & n11["• HBV/HCV
• Chronic bacterial infections
• ASO (strep)
• Recent Hx of infection
• Schistosomiasis
• Echinococcosis
• Malaria"] & n12["• SLE: ANA, ds DNA, C3/C4
    • Sjogren ANA, Anti-Ro/La, RF
    • RA: RF, ANA, Anti-CCP"]
    n8 -- infection present --> n23["Treat Underlying Illness"]
    n8 -- no infection --> n24["• <ins>Screen for for Monocolonoal Gammopathy (SPEP/UPEP/FLC) </ins>
    • Complement levels
    • Compliment activation (C3d, Bb, sMAC)
    • Genetic testing"]
    n10 --> n17(["Screening positive"]) & n20(["Screening negative"])
    n11 --> n17 & n20
    n12 --> n17 & n20
    n17 --> n21["Consult appropriate Specialist and Treat Underlying Illness"]
    n20 --> n22(["Ideopathic Disease/Indolent (ICGN)"])
    n24 --> n30["• No Monoclonal Gammopathy
    • moderate to severe disease
    • >1g/d Proteinuria
    • Declining function for at least 6 months"] & n31(["Monoclonal Gammopathy found"])
    n31 --> n32["Consult appropriate Specialist and Treat Underlying Illness"]
    n30 --> n33["• MMF + steroids
    • Supportive Therapy"] & n34["**Recently FDA approved therapy not yet in guidlines**
    • Iptocopan (Factor B inhibtor): approved for C3GN 3/2025
    • Pegcetocoplan (C3 ingibitor): approved for C3GN 7/2025"]
    n1@{ shape: rounded}
    n2@{ shape: rounded}
    n3@{ shape: rounded}
    n8@{ shape: rounded}
    n10@{ shape: rounded}
    n11@{ shape: rounded}
    n12@{ shape: rounded}
    n30@{ shape: rounded}
    style A fill:#616161,color:#FFFFFF
    style n1 fill:#757575,color:#FFFFFF
    style n2 fill:#757575,color:#FFFFFF
    style n3 fill:#757575,color:#FFFFFF
    style n4 fill:#757575,color:#FFFFFF
    style n6 fill:#757575,color:#FFFFFF
    style n7 fill:#D50000,color:#FFFFFF
    style n8 fill:#757575,color:#FFFFFF
    style n9 fill:#D50000,color:#FFFFFF
    style n10 fill:#757575,color:#FFFFFF
    style n11 color:#FFFFFF,fill:#757575
    style n12 fill:#757575,color:#FFFFFF
    style n23 fill:#D50000,color:#FFFFFF
    style n24 fill:#D50000,color:#FFFFFF
    style n17 fill:#757575,color:#FFFFFF
    style n20 fill:#757575,color:#FFFFFF
    style n21 color:#FFFFFF,fill:#D50000
    style n22 fill:#757575,color:#FFFFFF
    style n30 color:#FFFFFF,fill:#757575
    style n31 fill:#757575,color:#FFFFFF
    style n32 fill:#D50000,color:#FFFFFF
    style n33 fill:#D50000,color:#FFFFFF
    style n34 fill:#D50000,color:#FFFFFF
```
### ICGN
```mermaid
---
config:
  theme: redux
---
flowchart TD
    n22(["Ideopathic Disease/Indolent (ICGN)"]) --> n25["• Proteinuria &lt; 3.5 g/dl
     • Nephrotic Syndrome Abscent
     • Normal eGFR"] & n26["• Nephrotic Syndrome Present
     • Normal/near normal eGFR"] & n27["• Abnomral kidney function
      Active urine sedement w/out Nephrotic Syndrome"] & n28["Rapidly progressive Crescentic ICGN"] & n29["eGFR &lt;30"]
    n25 --> n35["• Supportive therapy w/RASi
    • Monitor Proteinuria and eGFR regularly"]
    n26 --> n36["**Can trial limited couse of steroids**
    • Prednisone 1mg/kg/day (60-80mg/day max) for 6-12 week --&gt; then taper to Every Other Day therapy over 6-8 months
    • IF &lt;30% reduction in proteinuria 12-16 weeks taper and DC steroids
    • If contraindication to steroids, can trial CNI
    • Extended Steroid use not encouraged"]
    n27 --> n37["Steroids pluss supportive Care
    • Prednisone 1mg/kg/day (60-80mg/day max) for 12-16 week"]
    n28 --> n38["Cyclophosphamide + Steroids similar to ANCA Vasculitis"]
    n29 --> n39["• Suporative therapy and evaluation for kidney transplant in due course
    • Unless kidney bx shows active necrotizing cresentic glomerulonephritis or other reason to support Immunosuppression"]
    n38 --> n40["See table below for"]
    n37 --> n41["•Stabilaztion/improvement of function
     or
    • > 30% reduction of proteinuria"]
    n41 -- yes --> n43["**Adequate Response**
    • Gradually taper and DC steroids"]
    n41 -- No --> n44["Prednisone 20mg/day + MMF 6-12months"]
    n44 --> n45["**No improvment**
    • Kidney function
    • Hematuria
    • Proteinuria"]
    n45 --> n46["Consider Repeat kidney bx"]
    n46 --> n47(["Active GN"])
    n47 --> n48@{ label: "Cyclophosphamide 2mg/kg/day (max dose of 200mg/d in adults) w/prednison 10mg/day\n    • Adjust for abnormal renal function\n    • Reduce dose by 25% in patient's over 60" } & n49["Rituximab 1g followed by a second dose of 1g 14 days later
    • Repeat this 2g regimen at 6 months"]
    n48 --> n50["3-6 months of no response discontinue immunosupression and continue Supportive Therapy"]
    n49 --> n50
    n25@{ shape: rounded}
    n26@{ shape: rounded}
    n27@{ shape: rounded}
    n28@{ shape: rounded}
    n29@{ shape: rounded}
    n41@{ shape: rounded}
    n43@{ shape: rect}
    n45@{ shape: rounded}
    n46@{ shape: rounded}
    n48@{ shape: rect}
    style n22 fill:#757575,color:#FFFFFF
    style n25 fill:#757575,color:#FFFFFF
    style n26 fill:#757575,color:#FFFFFF
    style n27 fill:#757575,color:#FFFFFF
    style n28 fill:#757575,color:#FFFFFF
    style n29 fill:#757575,color:#FFFFFF
    style n35 fill:#D50000,color:#FFFFFF
    style n36 fill:#D50000,color:#FFFFFF
    style n37 fill:#D50000,color:#FFFFFF
    style n38 fill:#D50000,color:#FFFFFF
    style n39 fill:#D50000,color:#FFFFFF
    style n40 fill:#D50000,color:#FFFFFF
    style n41 fill:#757575,color:#FFFFFF
    style n43 fill:#D50000,color:#FFFFFF
    style n44 color:#FFFFFF,fill:#D50000
    style n45 fill:#757575,color:#FFFFFF
    style n46 fill:#757575,color:#FFFFFF
    style n47 fill:#757575,color:#FFFFFF
    style n48 color:#FFFFFF,fill:#D50000
    style n49 color:#FFFFFF,fill:#D50000
    style n50 fill:#D50000,color:#FFFFFF
```
### Cyclophosphamide Dosing

|Oral Cyclophosphamide|IV Cyclophosphamide|
|---------------------|-------------------|
|• 2mg/kg/day for 3months|• 15mg/kg at weeks: 0, 2, 4, 7, 10, 13 (16, 19, 21, 24 if required)|
|<ins>Reduction for Age and function</ins>|<ins>Reduction for Age and function</ins>|
| • 60 y/o: 1.5mg/kg/day|• 60 y/o: 12.5mg/kg/day|
| • 70 y/o: 1mg/kg/day| • 70 y/o: 10mg/kg/day|
| • Reduce by 0.5mg/kg/day for eGFR < 30| • Reduce by 2.5mg/kg for eGFR < 30|


### Prednisone Taper
|Week|Patient's <50kg|Patient's 50-70kg|Patient's >75kg|
|----|-----|-------|-----|
|1   |50mg |60mg   |75mg |
|2   |25mg |30mg   |40mg |
|3-4|20mg|25mg|30mg|
|5-6|15mg|20mg|25mg|
|7-8|12.5mg|15mg|20mg|
|9-10|10mg|12.5mg|15mg|
|11-12|7.5mg|10mg|12.5mg|
|13-14|5mg|7.5mg|10mg|
|15-16|5mg|5mg|7.5mg|
|17-18|5mg|5mg|7.5mg|
|19-20|5mg|5mg|5mg|
|21-22|5mg|5mg|5mg|
|23-52|5mg|5mg|5mg|
|>52|Investigator's local practice|Investigator's local practice|Investigator's local practice|



## **Sources**
 * [KDIGO GN Guidlines](https://kdigo.org/guidelines/gd/)
 * [C3 glomerulopathies general info](https://pmc.ncbi.nlm.nih.gov/articles/PMC10704907/)
 * [Developing Therapies for C3 Glomerulopathy](https://khi.asn-online.org/uploads/developing_therapies_for_c3_glomerulopathy__report.18.pdf)
 * [Efficacy and Safety of Iptacopan i nPatient w/C3 Glomerulopathy](https://www.sciencedirect.com/science/article/pii/S2468024924023222)
 * [Alternative Complement pathway inhibition w/iptacopan for treatment of C3G](https://pubmed.ncbi.nlm.nih.gov/36217526/)
 * [Phase 3 Trial of Pegcetacoplan fof Patient with C3G or IC-MPGN](https://journals.lww.com/jasn/pages/articleviewer.aspx?year=2024&issue=10001&article=00313&type=Fulltext)
 * [Safety and EFficacy of Pegcetacoplan](https://pmc.ncbi.nlm.nih.gov/articles/PMC10658235/)
 * [MMF in Combination w/Steroids for C3G Case series](https://pubmed.ncbi.nlm.nih.gov/29326307/)
 * [MMR in C3G and Pathogenic Drivers of the Disease](https://pubmed.ncbi.nlm.nih.gov/32816888/)
 * [C5 Convertase blockade in MPGN](https://www.sciencedirect.com/science/article/abs/pii/S0272638619301003)
 * [Safety and Efficacy of Avacopan in Patients w/C3G](https://pubmed.ncbi.nlm.nih.gov/39392695/)
